nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—ABCB1—peripheral nervous system neoplasm	0.26	1	CbGaD
Dabrafenib—ABCG2—Topotecan—peripheral nervous system neoplasm	0.072	0.166	CbGbCtD
Dabrafenib—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0499	0.115	CbGbCtD
Dabrafenib—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.0357	0.082	CbGbCtD
Dabrafenib—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0307	0.0707	CbGbCtD
Dabrafenib—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.0287	0.0659	CbGbCtD
Dabrafenib—ABCG2—Etoposide—peripheral nervous system neoplasm	0.0282	0.0648	CbGbCtD
Dabrafenib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.026	0.0597	CbGbCtD
Dabrafenib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.026	0.0597	CbGbCtD
Dabrafenib—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.0192	0.0442	CbGbCtD
Dabrafenib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.018	0.0414	CbGbCtD
Dabrafenib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0156	0.0358	CbGbCtD
Dabrafenib—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.015	0.0345	CbGbCtD
Dabrafenib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0145	0.0333	CbGbCtD
Dabrafenib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0111	0.0255	CbGbCtD
Dabrafenib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0103	0.0238	CbGbCtD
Dabrafenib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0102	0.0234	CbGbCtD
Dabrafenib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00693	0.0159	CbGbCtD
Dabrafenib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00664	0.0153	CbGbCtD
Dabrafenib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00609	0.014	CbGbCtD
Dabrafenib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00415	0.00955	CbGbCtD
Dabrafenib—Insomnia—Vincristine—peripheral nervous system neoplasm	0.00015	0.000799	CcSEcCtD
Dabrafenib—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.00015	0.000797	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000149	0.000792	CcSEcCtD
Dabrafenib—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000149	0.000791	CcSEcCtD
Dabrafenib—Dermatitis bullous—Doxorubicin—peripheral nervous system neoplasm	0.000149	0.00079	CcSEcCtD
Dabrafenib—Leukopenia—Etoposide—peripheral nervous system neoplasm	0.000148	0.000785	CcSEcCtD
Dabrafenib—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000147	0.000784	CcSEcCtD
Dabrafenib—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000147	0.000782	CcSEcCtD
Dabrafenib—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000147	0.000782	CcSEcCtD
Dabrafenib—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000147	0.000781	CcSEcCtD
Dabrafenib—Infection—Cisplatin—peripheral nervous system neoplasm	0.000146	0.000776	CcSEcCtD
Dabrafenib—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000146	0.000775	CcSEcCtD
Dabrafenib—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000145	0.000769	CcSEcCtD
Dabrafenib—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000145	0.000769	CcSEcCtD
Dabrafenib—Rash—Topotecan—peripheral nervous system neoplasm	0.000145	0.000769	CcSEcCtD
Dabrafenib—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000145	0.000768	CcSEcCtD
Dabrafenib—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000144	0.000768	CcSEcCtD
Dabrafenib—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000144	0.000766	CcSEcCtD
Dabrafenib—Cough—Etoposide—peripheral nervous system neoplasm	0.000144	0.000765	CcSEcCtD
Dabrafenib—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.000144	0.000765	CcSEcCtD
Dabrafenib—Blood creatinine increased—Epirubicin—peripheral nervous system neoplasm	0.000144	0.000765	CcSEcCtD
Dabrafenib—Headache—Topotecan—peripheral nervous system neoplasm	0.000144	0.000764	CcSEcCtD
Dabrafenib—Rash—Tretinoin—peripheral nervous system neoplasm	0.000143	0.000763	CcSEcCtD
Dabrafenib—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000143	0.000763	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000143	0.000763	CcSEcCtD
Dabrafenib—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000143	0.000762	CcSEcCtD
Dabrafenib—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000143	0.000762	CcSEcCtD
Dabrafenib—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000143	0.000762	CcSEcCtD
Dabrafenib—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000143	0.000759	CcSEcCtD
Dabrafenib—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000759	CcSEcCtD
Dabrafenib—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000143	0.000759	CcSEcCtD
Dabrafenib—Hyponatraemia—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000758	CcSEcCtD
Dabrafenib—Headache—Tretinoin—peripheral nervous system neoplasm	0.000143	0.000758	CcSEcCtD
Dabrafenib—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000143	0.000758	CcSEcCtD
Dabrafenib—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000142	0.000757	CcSEcCtD
Dabrafenib—Constipation—Vincristine—peripheral nervous system neoplasm	0.000142	0.000756	CcSEcCtD
Dabrafenib—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	0.000142	0.000755	CcSEcCtD
Dabrafenib—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000142	0.000755	CcSEcCtD
Dabrafenib—Rash—Melphalan—peripheral nervous system neoplasm	0.000142	0.000753	CcSEcCtD
Dabrafenib—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000141	0.000752	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000141	0.00075	CcSEcCtD
Dabrafenib—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000748	CcSEcCtD
Dabrafenib—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000746	CcSEcCtD
Dabrafenib—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000743	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000139	0.000742	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000735	CcSEcCtD
Dabrafenib—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000137	0.00073	CcSEcCtD
Dabrafenib—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000137	0.00073	CcSEcCtD
Dabrafenib—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000137	0.000729	CcSEcCtD
Dabrafenib—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000136	0.000725	CcSEcCtD
Dabrafenib—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000136	0.000725	CcSEcCtD
Dabrafenib—Nausea—Topotecan—peripheral nervous system neoplasm	0.000136	0.000724	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000136	0.000723	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000135	0.00072	CcSEcCtD
Dabrafenib—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000135	0.000719	CcSEcCtD
Dabrafenib—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000135	0.000719	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000134	0.000712	CcSEcCtD
Dabrafenib—Infection—Etoposide—peripheral nervous system neoplasm	0.000134	0.000711	CcSEcCtD
Dabrafenib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000133	0.00071	CcSEcCtD
Dabrafenib—Nausea—Melphalan—peripheral nervous system neoplasm	0.000133	0.000709	CcSEcCtD
Dabrafenib—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000708	CcSEcCtD
Dabrafenib—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.000702	CcSEcCtD
Dabrafenib—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000132	0.000701	CcSEcCtD
Dabrafenib—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000131	0.000698	CcSEcCtD
Dabrafenib—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000131	0.000698	CcSEcCtD
Dabrafenib—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000131	0.000695	CcSEcCtD
Dabrafenib—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000692	CcSEcCtD
Dabrafenib—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.00013	0.000692	CcSEcCtD
Dabrafenib—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	0.00013	0.000692	CcSEcCtD
Dabrafenib—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.00069	CcSEcCtD
Dabrafenib—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000687	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.00068	CcSEcCtD
Dabrafenib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000128	0.000679	CcSEcCtD
Dabrafenib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000127	0.000677	CcSEcCtD
Dabrafenib—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000127	0.000676	CcSEcCtD
Dabrafenib—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000675	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000127	0.000675	CcSEcCtD
Dabrafenib—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000126	0.000669	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000666	CcSEcCtD
Dabrafenib—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000124	0.00066	CcSEcCtD
Dabrafenib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000124	0.000658	CcSEcCtD
Dabrafenib—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000122	0.000651	CcSEcCtD
Dabrafenib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000122	0.000649	CcSEcCtD
Dabrafenib—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.00064	CcSEcCtD
Dabrafenib—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000636	CcSEcCtD
Dabrafenib—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000119	0.000634	CcSEcCtD
Dabrafenib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000629	CcSEcCtD
Dabrafenib—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000629	CcSEcCtD
Dabrafenib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000118	0.000629	CcSEcCtD
Dabrafenib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000118	0.000627	CcSEcCtD
Dabrafenib—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000117	0.000624	CcSEcCtD
Dabrafenib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000117	0.000622	CcSEcCtD
Dabrafenib—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000618	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000116	0.000618	CcSEcCtD
Dabrafenib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000116	0.000618	CcSEcCtD
Dabrafenib—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000116	0.000617	CcSEcCtD
Dabrafenib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000613	CcSEcCtD
Dabrafenib—Constipation—Etoposide—peripheral nervous system neoplasm	0.000115	0.000612	CcSEcCtD
Dabrafenib—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000611	CcSEcCtD
Dabrafenib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000115	0.00061	CcSEcCtD
Dabrafenib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000114	0.000606	CcSEcCtD
Dabrafenib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000114	0.000605	CcSEcCtD
Dabrafenib—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000113	0.0006	CcSEcCtD
Dabrafenib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000593	CcSEcCtD
Dabrafenib—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000589	CcSEcCtD
Dabrafenib—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.00011	0.000587	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.00011	0.000585	CcSEcCtD
Dabrafenib—Dizziness—Vincristine—peripheral nervous system neoplasm	0.00011	0.000584	CcSEcCtD
Dabrafenib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.00011	0.000583	CcSEcCtD
Dabrafenib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000582	CcSEcCtD
Dabrafenib—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000582	CcSEcCtD
Dabrafenib—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000109	0.000578	CcSEcCtD
Dabrafenib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000109	0.000578	CcSEcCtD
Dabrafenib—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000108	0.000576	CcSEcCtD
Dabrafenib—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000108	0.000574	CcSEcCtD
Dabrafenib—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000572	CcSEcCtD
Dabrafenib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000568	CcSEcCtD
Dabrafenib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000567	CcSEcCtD
Dabrafenib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000106	0.000566	CcSEcCtD
Dabrafenib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000106	0.000566	CcSEcCtD
Dabrafenib—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000566	CcSEcCtD
Dabrafenib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000565	CcSEcCtD
Dabrafenib—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000106	0.000562	CcSEcCtD
Dabrafenib—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000105	0.000561	CcSEcCtD
Dabrafenib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000558	CcSEcCtD
Dabrafenib—Rash—Vincristine—peripheral nervous system neoplasm	0.000105	0.000557	CcSEcCtD
Dabrafenib—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000105	0.000557	CcSEcCtD
Dabrafenib—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000556	CcSEcCtD
Dabrafenib—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000555	CcSEcCtD
Dabrafenib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000555	CcSEcCtD
Dabrafenib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000554	CcSEcCtD
Dabrafenib—Headache—Vincristine—peripheral nervous system neoplasm	0.000104	0.000554	CcSEcCtD
Dabrafenib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000549	CcSEcCtD
Dabrafenib—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000102	0.000545	CcSEcCtD
Dabrafenib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000101	0.000535	CcSEcCtD
Dabrafenib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	9.93e-05	0.000528	CcSEcCtD
Dabrafenib—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	9.92e-05	0.000527	CcSEcCtD
Dabrafenib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	9.88e-05	0.000525	CcSEcCtD
Dabrafenib—Nausea—Vincristine—peripheral nervous system neoplasm	9.87e-05	0.000525	CcSEcCtD
Dabrafenib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	9.83e-05	0.000523	CcSEcCtD
Dabrafenib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	9.71e-05	0.000516	CcSEcCtD
Dabrafenib—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	9.68e-05	0.000515	CcSEcCtD
Dabrafenib—Asthenia—Etoposide—peripheral nervous system neoplasm	9.66e-05	0.000514	CcSEcCtD
Dabrafenib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	9.66e-05	0.000513	CcSEcCtD
Dabrafenib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	9.64e-05	0.000512	CcSEcCtD
Dabrafenib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	9.63e-05	0.000512	CcSEcCtD
Dabrafenib—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	9.59e-05	0.00051	CcSEcCtD
Dabrafenib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	9.57e-05	0.000509	CcSEcCtD
Dabrafenib—Chills—Epirubicin—peripheral nervous system neoplasm	9.53e-05	0.000507	CcSEcCtD
Dabrafenib—Pruritus—Etoposide—peripheral nervous system neoplasm	9.52e-05	0.000506	CcSEcCtD
Dabrafenib—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	9.49e-05	0.000504	CcSEcCtD
Dabrafenib—Alopecia—Epirubicin—peripheral nervous system neoplasm	9.39e-05	0.000499	CcSEcCtD
Dabrafenib—Vomiting—Cisplatin—peripheral nervous system neoplasm	9.34e-05	0.000497	CcSEcCtD
Dabrafenib—Mental disorder—Epirubicin—peripheral nervous system neoplasm	9.31e-05	0.000495	CcSEcCtD
Dabrafenib—Rash—Cisplatin—peripheral nervous system neoplasm	9.27e-05	0.000493	CcSEcCtD
Dabrafenib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	9.26e-05	0.000492	CcSEcCtD
Dabrafenib—Erythema—Epirubicin—peripheral nervous system neoplasm	9.25e-05	0.000492	CcSEcCtD
Dabrafenib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	9.25e-05	0.000492	CcSEcCtD
Dabrafenib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	9.21e-05	0.00049	CcSEcCtD
Dabrafenib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	9.18e-05	0.000488	CcSEcCtD
Dabrafenib—Back pain—Epirubicin—peripheral nervous system neoplasm	8.94e-05	0.000476	CcSEcCtD
Dabrafenib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	8.92e-05	0.000474	CcSEcCtD
Dabrafenib—Dizziness—Etoposide—peripheral nervous system neoplasm	8.9e-05	0.000473	CcSEcCtD
Dabrafenib—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	8.89e-05	0.000473	CcSEcCtD
Dabrafenib—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	8.88e-05	0.000472	CcSEcCtD
Dabrafenib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	8.86e-05	0.000471	CcSEcCtD
Dabrafenib—Chills—Doxorubicin—peripheral nervous system neoplasm	8.82e-05	0.000469	CcSEcCtD
Dabrafenib—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	8.78e-05	0.000467	CcSEcCtD
Dabrafenib—Nausea—Cisplatin—peripheral nervous system neoplasm	8.73e-05	0.000464	CcSEcCtD
Dabrafenib—Vision blurred—Epirubicin—peripheral nervous system neoplasm	8.71e-05	0.000463	CcSEcCtD
Dabrafenib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	8.68e-05	0.000462	CcSEcCtD
Dabrafenib—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	8.61e-05	0.000458	CcSEcCtD
Dabrafenib—Vomiting—Etoposide—peripheral nervous system neoplasm	8.56e-05	0.000455	CcSEcCtD
Dabrafenib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	8.56e-05	0.000455	CcSEcCtD
Dabrafenib—Erythema—Doxorubicin—peripheral nervous system neoplasm	8.56e-05	0.000455	CcSEcCtD
Dabrafenib—Anaemia—Epirubicin—peripheral nervous system neoplasm	8.55e-05	0.000454	CcSEcCtD
Dabrafenib—Rash—Etoposide—peripheral nervous system neoplasm	8.49e-05	0.000451	CcSEcCtD
Dabrafenib—Dermatitis—Etoposide—peripheral nervous system neoplasm	8.48e-05	0.000451	CcSEcCtD
Dabrafenib—Headache—Etoposide—peripheral nervous system neoplasm	8.43e-05	0.000448	CcSEcCtD
Dabrafenib—Leukopenia—Epirubicin—peripheral nervous system neoplasm	8.28e-05	0.00044	CcSEcCtD
Dabrafenib—Back pain—Doxorubicin—peripheral nervous system neoplasm	8.28e-05	0.00044	CcSEcCtD
Dabrafenib—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	8.23e-05	0.000437	CcSEcCtD
Dabrafenib—Cough—Epirubicin—peripheral nervous system neoplasm	8.07e-05	0.000429	CcSEcCtD
Dabrafenib—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	8.06e-05	0.000429	CcSEcCtD
Dabrafenib—Nausea—Etoposide—peripheral nervous system neoplasm	8e-05	0.000425	CcSEcCtD
Dabrafenib—Hypertension—Epirubicin—peripheral nervous system neoplasm	7.98e-05	0.000424	CcSEcCtD
Dabrafenib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	7.91e-05	0.00042	CcSEcCtD
Dabrafenib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	7.87e-05	0.000419	CcSEcCtD
Dabrafenib—Myalgia—Epirubicin—peripheral nervous system neoplasm	7.87e-05	0.000419	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	7.82e-05	0.000416	CcSEcCtD
Dabrafenib—Dry mouth—Epirubicin—peripheral nervous system neoplasm	7.7e-05	0.000409	CcSEcCtD
Dabrafenib—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	7.66e-05	0.000407	CcSEcCtD
Dabrafenib—Oedema—Epirubicin—peripheral nervous system neoplasm	7.55e-05	0.000401	CcSEcCtD
Dabrafenib—Infection—Epirubicin—peripheral nervous system neoplasm	7.5e-05	0.000399	CcSEcCtD
Dabrafenib—Cough—Doxorubicin—peripheral nervous system neoplasm	7.47e-05	0.000397	CcSEcCtD
Dabrafenib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	7.4e-05	0.000393	CcSEcCtD
Dabrafenib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	7.39e-05	0.000393	CcSEcCtD
Dabrafenib—Hypertension—Doxorubicin—peripheral nervous system neoplasm	7.39e-05	0.000393	CcSEcCtD
Dabrafenib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	7.33e-05	0.00039	CcSEcCtD
Dabrafenib—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	7.3e-05	0.000388	CcSEcCtD
Dabrafenib—Myalgia—Doxorubicin—peripheral nervous system neoplasm	7.28e-05	0.000387	CcSEcCtD
Dabrafenib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	7.28e-05	0.000387	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	7.23e-05	0.000385	CcSEcCtD
Dabrafenib—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	7.12e-05	0.000379	CcSEcCtD
Dabrafenib—Hypotension—Epirubicin—peripheral nervous system neoplasm	7.05e-05	0.000375	CcSEcCtD
Dabrafenib—Oedema—Doxorubicin—peripheral nervous system neoplasm	6.98e-05	0.000371	CcSEcCtD
Dabrafenib—Infection—Doxorubicin—peripheral nervous system neoplasm	6.94e-05	0.000369	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	6.88e-05	0.000366	CcSEcCtD
Dabrafenib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	6.85e-05	0.000364	CcSEcCtD
Dabrafenib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	6.84e-05	0.000363	CcSEcCtD
Dabrafenib—Insomnia—Epirubicin—peripheral nervous system neoplasm	6.83e-05	0.000363	CcSEcCtD
Dabrafenib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	6.78e-05	0.000361	CcSEcCtD
Dabrafenib—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	6.75e-05	0.000359	CcSEcCtD
Dabrafenib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	6.56e-05	0.000349	CcSEcCtD
Dabrafenib—Hypotension—Doxorubicin—peripheral nervous system neoplasm	6.52e-05	0.000347	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	6.52e-05	0.000346	CcSEcCtD
Dabrafenib—Fatigue—Epirubicin—peripheral nervous system neoplasm	6.51e-05	0.000346	CcSEcCtD
Dabrafenib—Constipation—Epirubicin—peripheral nervous system neoplasm	6.45e-05	0.000343	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	6.36e-05	0.000338	CcSEcCtD
Dabrafenib—Insomnia—Doxorubicin—peripheral nervous system neoplasm	6.32e-05	0.000336	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	6.17e-05	0.000328	CcSEcCtD
Dabrafenib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	6.07e-05	0.000323	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	6.03e-05	0.000321	CcSEcCtD
Dabrafenib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	6.02e-05	0.00032	CcSEcCtD
Dabrafenib—Constipation—Doxorubicin—peripheral nervous system neoplasm	5.97e-05	0.000317	CcSEcCtD
Dabrafenib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	5.97e-05	0.000317	CcSEcCtD
Dabrafenib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	5.97e-05	0.000317	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	5.71e-05	0.000304	CcSEcCtD
Dabrafenib—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	5.56e-05	0.000296	CcSEcCtD
Dabrafenib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	5.52e-05	0.000293	CcSEcCtD
Dabrafenib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	5.52e-05	0.000293	CcSEcCtD
Dabrafenib—Asthenia—Epirubicin—peripheral nervous system neoplasm	5.41e-05	0.000288	CcSEcCtD
Dabrafenib—Pruritus—Epirubicin—peripheral nervous system neoplasm	5.34e-05	0.000284	CcSEcCtD
Dabrafenib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	5.16e-05	0.000275	CcSEcCtD
Dabrafenib—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	5.14e-05	0.000274	CcSEcCtD
Dabrafenib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	5.01e-05	0.000266	CcSEcCtD
Dabrafenib—Dizziness—Epirubicin—peripheral nervous system neoplasm	4.99e-05	0.000265	CcSEcCtD
Dabrafenib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	4.94e-05	0.000263	CcSEcCtD
Dabrafenib—Vomiting—Epirubicin—peripheral nervous system neoplasm	4.8e-05	0.000255	CcSEcCtD
Dabrafenib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	4.78e-05	0.000254	CcSEcCtD
Dabrafenib—Rash—Epirubicin—peripheral nervous system neoplasm	4.76e-05	0.000253	CcSEcCtD
Dabrafenib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	4.75e-05	0.000253	CcSEcCtD
Dabrafenib—Headache—Epirubicin—peripheral nervous system neoplasm	4.73e-05	0.000251	CcSEcCtD
Dabrafenib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	4.62e-05	0.000245	CcSEcCtD
Dabrafenib—Nausea—Epirubicin—peripheral nervous system neoplasm	4.48e-05	0.000238	CcSEcCtD
Dabrafenib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	4.44e-05	0.000236	CcSEcCtD
Dabrafenib—Rash—Doxorubicin—peripheral nervous system neoplasm	4.4e-05	0.000234	CcSEcCtD
Dabrafenib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	4.4e-05	0.000234	CcSEcCtD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—NRAS—peripheral nervous system neoplasm	4.39e-05	0.000376	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—NRAS—peripheral nervous system neoplasm	4.39e-05	0.000376	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—HRAS—peripheral nervous system neoplasm	4.38e-05	0.000375	CbGpPWpGaD
Dabrafenib—Headache—Doxorubicin—peripheral nervous system neoplasm	4.37e-05	0.000233	CcSEcCtD
Dabrafenib—RAF1—Signaling by EGFR—NRAS—peripheral nervous system neoplasm	4.35e-05	0.000372	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	4.35e-05	0.000372	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—NRAS—peripheral nervous system neoplasm	4.32e-05	0.00037	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—HGF—peripheral nervous system neoplasm	4.32e-05	0.000369	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—NRAS—peripheral nervous system neoplasm	4.31e-05	0.000369	CbGpPWpGaD
Dabrafenib—RAF1—ErbB1 downstream signaling—AKT1—peripheral nervous system neoplasm	4.3e-05	0.000368	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—NRAS—peripheral nervous system neoplasm	4.29e-05	0.000367	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VIP—peripheral nervous system neoplasm	4.28e-05	0.000367	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	4.27e-05	0.000366	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—MYC—peripheral nervous system neoplasm	4.26e-05	0.000365	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	4.25e-05	0.000364	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TP53—peripheral nervous system neoplasm	4.24e-05	0.000363	CbGpPWpGaD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—HRAS—peripheral nervous system neoplasm	4.24e-05	0.000363	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—AKT1—peripheral nervous system neoplasm	4.24e-05	0.000363	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PPP3R1—peripheral nervous system neoplasm	4.23e-05	0.000362	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NME1—peripheral nervous system neoplasm	4.22e-05	0.000361	CbGpPWpGaD
Dabrafenib—BRAF—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	4.21e-05	0.00036	CbGpPWpGaD
Dabrafenib—Nausea—Doxorubicin—peripheral nervous system neoplasm	4.15e-05	0.000221	CcSEcCtD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	4.11e-05	0.000352	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	4.1e-05	0.000351	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—HRAS—peripheral nervous system neoplasm	4.08e-05	0.000349	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GNS—peripheral nervous system neoplasm	4.08e-05	0.000349	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—COX2—peripheral nervous system neoplasm	4.07e-05	0.000348	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	4.06e-05	0.000348	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—AKT1—peripheral nervous system neoplasm	4e-05	0.000342	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.99e-05	0.000341	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ENO2—peripheral nervous system neoplasm	3.97e-05	0.00034	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	3.95e-05	0.000338	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SLC2A1—peripheral nervous system neoplasm	3.94e-05	0.000337	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	3.93e-05	0.000336	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	3.92e-05	0.000336	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NME1—peripheral nervous system neoplasm	3.91e-05	0.000335	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NTS—peripheral nervous system neoplasm	3.91e-05	0.000335	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PPP3R1—peripheral nervous system neoplasm	3.91e-05	0.000334	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	3.89e-05	0.000333	CbGpPWpGaD
Dabrafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	3.87e-05	0.000331	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—AKT1—peripheral nervous system neoplasm	3.87e-05	0.000331	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—HRAS—peripheral nervous system neoplasm	3.85e-05	0.00033	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.85e-05	0.000329	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	3.85e-05	0.000329	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	3.79e-05	0.000324	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—ERBB2—peripheral nervous system neoplasm	3.77e-05	0.000323	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—COX2—peripheral nervous system neoplasm	3.76e-05	0.000322	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	3.76e-05	0.000321	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CD55—peripheral nervous system neoplasm	3.75e-05	0.000321	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NCAM1—peripheral nervous system neoplasm	3.74e-05	0.00032	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	3.7e-05	0.000316	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—HRAS—peripheral nervous system neoplasm	3.68e-05	0.000315	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	3.63e-05	0.000311	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.63e-05	0.00031	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	3.63e-05	0.00031	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—HRAS—peripheral nervous system neoplasm	3.61e-05	0.000309	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—AKT1—peripheral nervous system neoplasm	3.61e-05	0.000309	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—AKT1—peripheral nervous system neoplasm	3.58e-05	0.000307	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—CASP3—peripheral nervous system neoplasm	3.57e-05	0.000305	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—ERBB2—peripheral nervous system neoplasm	3.56e-05	0.000304	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.5e-05	0.0003	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—peripheral nervous system neoplasm	3.5e-05	0.000299	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—HRAS—peripheral nervous system neoplasm	3.48e-05	0.000298	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MET—peripheral nervous system neoplasm	3.47e-05	0.000297	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—HRAS—peripheral nervous system neoplasm	3.46e-05	0.000296	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—HRAS—peripheral nervous system neoplasm	3.45e-05	0.000295	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—HRAS—peripheral nervous system neoplasm	3.45e-05	0.000295	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—HRAS—peripheral nervous system neoplasm	3.43e-05	0.000293	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	3.42e-05	0.000293	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—HRAS—peripheral nervous system neoplasm	3.41e-05	0.000292	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—AKT1—peripheral nervous system neoplasm	3.4e-05	0.000291	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ENO2—peripheral nervous system neoplasm	3.38e-05	0.00029	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.36e-05	0.000287	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—BCHE—peripheral nervous system neoplasm	3.36e-05	0.000287	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	3.34e-05	0.000286	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	3.25e-05	0.000278	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—HRAS—peripheral nervous system neoplasm	3.22e-05	0.000276	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—PTPN11—peripheral nervous system neoplasm	3.21e-05	0.000275	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—HRAS—peripheral nervous system neoplasm	3.21e-05	0.000275	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	3.21e-05	0.000275	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	3.21e-05	0.000275	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.2e-05	0.000274	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	3.2e-05	0.000274	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—AKT1—peripheral nervous system neoplasm	3.18e-05	0.000272	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	3.18e-05	0.000272	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—HRAS—peripheral nervous system neoplasm	3.16e-05	0.00027	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	3.16e-05	0.00027	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—TH—peripheral nervous system neoplasm	3.16e-05	0.00027	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	3.15e-05	0.00027	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—PTPN11—peripheral nervous system neoplasm	3.15e-05	0.00027	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	3.14e-05	0.000269	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—AKT1—peripheral nervous system neoplasm	3.07e-05	0.000263	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	3.06e-05	0.000262	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.05e-05	0.000261	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	3.04e-05	0.00026	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—AKT1—peripheral nervous system neoplasm	3.04e-05	0.00026	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—NRAS—peripheral nervous system neoplasm	3.04e-05	0.00026	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—HRAS—peripheral nervous system neoplasm	3.03e-05	0.00026	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	3.03e-05	0.000259	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—AKT1—peripheral nervous system neoplasm	3.01e-05	0.000258	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—NRAS—peripheral nervous system neoplasm	2.99e-05	0.000256	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.97e-05	0.000255	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.97e-05	0.000254	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.96e-05	0.000254	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	2.96e-05	0.000253	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	2.94e-05	0.000252	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNB1—peripheral nervous system neoplasm	2.93e-05	0.000251	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	2.91e-05	0.000249	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	2.91e-05	0.000249	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—NRAS—peripheral nervous system neoplasm	2.87e-05	0.000246	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	2.84e-05	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PTPN11—peripheral nervous system neoplasm	2.84e-05	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	2.83e-05	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	2.83e-05	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—AKT1—peripheral nervous system neoplasm	2.83e-05	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	2.81e-05	0.00024	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—AKT1—peripheral nervous system neoplasm	2.79e-05	0.000239	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	2.78e-05	0.000238	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.78e-05	0.000238	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	2.77e-05	0.000237	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	2.75e-05	0.000235	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.74e-05	0.000234	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SLC2A1—peripheral nervous system neoplasm	2.73e-05	0.000233	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	2.72e-05	0.000233	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—NRAS—peripheral nervous system neoplasm	2.71e-05	0.000232	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—AKT1—peripheral nervous system neoplasm	2.68e-05	0.000229	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ENO2—peripheral nervous system neoplasm	2.67e-05	0.000228	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	2.67e-05	0.000228	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.6e-05	0.000223	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—GNAS—peripheral nervous system neoplasm	2.58e-05	0.00022	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	2.56e-05	0.000219	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.54e-05	0.000217	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—ERBB2—peripheral nervous system neoplasm	2.54e-05	0.000217	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GNS—peripheral nervous system neoplasm	2.53e-05	0.000217	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ABCB1—peripheral nervous system neoplasm	2.53e-05	0.000216	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	2.51e-05	0.000215	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ENO2—peripheral nervous system neoplasm	2.47e-05	0.000211	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NME1—peripheral nervous system neoplasm	2.43e-05	0.000208	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.42e-05	0.000207	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	2.37e-05	0.000203	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—COX2—peripheral nervous system neoplasm	2.34e-05	0.0002	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	2.32e-05	0.000199	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.3e-05	0.000197	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HGF—peripheral nervous system neoplasm	2.26e-05	0.000194	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—BCHE—peripheral nervous system neoplasm	2.26e-05	0.000193	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—ERBB2—peripheral nervous system neoplasm	2.24e-05	0.000192	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—HRAS—peripheral nervous system neoplasm	2.23e-05	0.000191	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HRAS—peripheral nervous system neoplasm	2.22e-05	0.00019	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.22e-05	0.00019	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	2.21e-05	0.000189	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTPN11—peripheral nervous system neoplasm	2.2e-05	0.000189	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—HRAS—peripheral nervous system neoplasm	2.19e-05	0.000187	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	2.15e-05	0.000184	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.15e-05	0.000184	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TH—peripheral nervous system neoplasm	2.12e-05	0.000181	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	2.11e-05	0.000181	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HRAS—peripheral nervous system neoplasm	2.1e-05	0.00018	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—BCHE—peripheral nervous system neoplasm	2.09e-05	0.000179	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.05e-05	0.000176	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	2.04e-05	0.000174	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.99e-05	0.00017	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—HRAS—peripheral nervous system neoplasm	1.98e-05	0.000169	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TH—peripheral nervous system neoplasm	1.96e-05	0.000168	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—AKT1—peripheral nervous system neoplasm	1.93e-05	0.000165	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—NRAS—peripheral nervous system neoplasm	1.93e-05	0.000165	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—NRAS—peripheral nervous system neoplasm	1.89e-05	0.000162	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.88e-05	0.000161	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—AKT1—peripheral nervous system neoplasm	1.85e-05	0.000159	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.85e-05	0.000158	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.81e-05	0.000155	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.81e-05	0.000155	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.76e-05	0.00015	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ERBB2—peripheral nervous system neoplasm	1.74e-05	0.000149	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—GNAS—peripheral nervous system neoplasm	1.73e-05	0.000148	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—NRAS—peripheral nervous system neoplasm	1.7e-05	0.000146	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ABCB1—peripheral nervous system neoplasm	1.7e-05	0.000145	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.67e-05	0.000143	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTPN11—peripheral nervous system neoplasm	1.65e-05	0.000141	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	1.64e-05	0.00014	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	1.6e-05	0.000137	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.57e-05	0.000135	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.54e-05	0.000132	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.54e-05	0.000131	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ENO2—peripheral nervous system neoplasm	1.53e-05	0.000131	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTPN11—peripheral nervous system neoplasm	1.52e-05	0.00013	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.49e-05	0.000127	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—peripheral nervous system neoplasm	1.45e-05	0.000124	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—HRAS—peripheral nervous system neoplasm	1.41e-05	0.000121	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—HRAS—peripheral nervous system neoplasm	1.39e-05	0.000119	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	1.36e-05	0.000116	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	1.34e-05	0.000114	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NRAS—peripheral nervous system neoplasm	1.33e-05	0.000113	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ERBB2—peripheral nervous system neoplasm	1.31e-05	0.000112	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1.3e-05	0.000111	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	1.3e-05	0.000111	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.26e-05	0.000108	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	1.25e-05	0.000107	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.25e-05	0.000107	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—AKT1—peripheral nervous system neoplasm	1.25e-05	0.000107	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.24e-05	0.000106	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—peripheral nervous system neoplasm	1.23e-05	0.000106	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—AKT1—peripheral nervous system neoplasm	1.22e-05	0.000105	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.22e-05	0.000104	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	1.22e-05	0.000104	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ERBB2—peripheral nervous system neoplasm	1.21e-05	0.000103	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.2e-05	0.000102	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	1.13e-05	9.66e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.11e-05	9.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.1e-05	9.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.09e-05	9.3e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.08e-05	9.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.07e-05	9.14e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	1.06e-05	9.08e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.06e-05	9.05e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	9.95e-06	8.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NRAS—peripheral nervous system neoplasm	9.93e-06	8.5e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	9.76e-06	8.35e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HRAS—peripheral nervous system neoplasm	9.69e-06	8.3e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NRAS—peripheral nervous system neoplasm	9.28e-06	7.94e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NRAS—peripheral nervous system neoplasm	9.17e-06	7.85e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	8.67e-06	7.42e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.64e-06	7.4e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—AKT1—peripheral nervous system neoplasm	8.56e-06	7.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—peripheral nervous system neoplasm	8.54e-06	7.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	8.44e-06	7.22e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	8.23e-06	7.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	7.95e-06	6.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.66e-06	6.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HRAS—peripheral nervous system neoplasm	7.27e-06	6.22e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.1e-06	6.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	7.02e-06	6.01e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	6.96e-06	5.95e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AKT1—peripheral nervous system neoplasm	6.95e-06	5.95e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.79e-06	5.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HRAS—peripheral nervous system neoplasm	6.71e-06	5.74e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.64e-06	5.68e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	6.54e-06	5.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.42e-06	5.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AKT1—peripheral nervous system neoplasm	6.41e-06	5.49e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.99e-06	5.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.98e-06	5.12e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—AKT1—peripheral nervous system neoplasm	5.92e-06	5.07e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	5.34e-06	4.57e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	5.24e-06	4.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.91e-06	4.2e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.7e-06	4.02e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AKT1—peripheral nervous system neoplasm	4.67e-06	4e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	4.33e-06	3.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.15e-06	3.55e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	2.68e-06	2.3e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	2.34e-06	2e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.44e-06	1.23e-05	CbGpPWpGaD
